Clinical Trial

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Study acronym: SUPPRESS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-07-30; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2022-03-06
Trial Details
NCT Number NCT04989725
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Metastatic Cancer, Oligoprogressive
Enrollment 46 participants
Start Date 2021-10-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-22